Aluminum phosphide poisoning. Toxic effect of phosphorus and its compounds
Conditions
Interventions
Intervention 1: Intervention group: the treatment protocol recommended by the Ministry of Health plus two vials of edaravone (60 mg in total) in 200 ml of 0.9% sodium chloride infusion solution for tw
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Aluminum phosphide poisoning
Exclusion criteria
Exclusion criteria: Negative silver nitrate test Age less than 18 and more than 60 years Concomitant poisoning with drugs or other compounds Heart failure disease Patients with asthma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of men who have an Ejection Fraction lower than 52%. Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;The proportion of females with an Ejection Fraction less than 54%. Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;The percentage of women with a left ventricular end-diastolic diameter greater than 52 mm. Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;Percentage of men with a left ventricular end-diastolic diameter greater than 59 mm. Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;The percentage of people whose left atrial volume is more than 34 cc/m2 in relation to body surface. Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;The percentage of people who have left ventricular stretch is less than- 20%. Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;The proportion of individuals with an initial diastolic velocity of the left ventricle below 6 cm/s. Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;Initial velocity of the mitral valve during diastole(E). Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;End-diastolic velocity of the mitral valve(A). Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;The percentage of people with a pulmonary artery systolic pressure(SPAP) greater than 35 mmHg. Timepoint: On the first, third and fifth day of the hospital stay. Method of measurement: Echocardiography.;The percentage of people with systolic blood pressure less than 90 mm Hg. Timepoint: Daily. Method of measurement: Sphygmomanomete | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammation and infection and bruising at the injection site. Timepoint: During hospitalization, one week after discharge. Method of measurement: Observation, examination.;?Anaphylactic shock. Timepoint: During hospitalization. Method of measurement: Observation, examination.;Skin complications. Timepoint: During hospitalization, one week after discharge. Method of measurement: Observation, examination.;Gait disturbance. Timepoint: Upon the initial occasion in which the patient is capable of ambulation. Method of measurement: Observation, examination.;The number of days hospitalized in the intensive care unit. Timepoint: At the time of discharge. Method of measurement: Examining the hospitalization file.;Length of hospital stay in the ward. Timepoint: At the time of discharge. Method of measurement: Examining the hospitalization file.;Mortality in hospitals. Timepoint: At the time of hospitalization. Method of measurement: Examining the hospitalization file.;Cardiac enzymes. Timepoint: First day, third day, fifth day of hospitalisation. Method of measurement: The laboratory kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Reza Mousavi
Mashhad University of Medical Sciences
Outcome results
None listed